Skip to main content

Table 2 Operative data of patients with reference to PCC administration

From: Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery

  Overall series Propensity score–matched pairs
  No PCC (n = 680) PCC (n = 291) p Value Pre-match SD No PCC (n = 225) PCC (n = 225) p Value Post-match SD
Type of surgery    0.009     0.901  
Isolated CABG 173 (25.4) 47 (16.2)   0.228 39 (17.3) 36 (16.0)   0.035
Isolated valve surgery 226 (33.2) 113 (38.8)   0.117 92 (40.9) 88 (39.1)   0.037
Valve surgery + CABG 154 (22.6) 64 (22.0)   0.014 47 (20.9) 53 (23.6)   0.065
Aortic surgery 127 (18.7) 67 (23.0)   0.106 47 (20.9) 48 (21.3)   0.01
CPB time, min 152 ± 64 148 ± 64 0.234 0.001 150 ± 65 152 ± 68 0.734 0.001
ACC time, min 111 ± 51 106 ± 49 0.157 0.002 104 ± 46 109 ± 50 0.410 0.002
Nadir Hct during CPB, % 22.9 ± 3.9 23.9 ± 3.6 <0.0001 0.071 23.4 ± 4.3 23.7 ± 3.7 0.305 0.019
  1. ACC aortic cross-clamp, CABG coronary artery bypass graft, CPB cardiopulmonary bypass, Hct haematocrit, PCC prothrombin complex concentrates, SD standard deviation
  2. Continuous values are reported as mean and standard deviation; nominal variables are reported as counts and (percentages)